Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10940
Title: Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
Austin Authors: Seeman, Ego ;Boonen, Steven;Borgström, Frederik;Vellas, Bruno;Aquino, Jean-Pierre;Semler, Jutta;Benhamou, Claude-Laurent;Kaufman, Jean-Marc;Reginster, Jean-Yves
Affiliation: Austin Health, University of Melbourne, Melbourne, Australia
Issue Date: 21-Dec-2009
Publication information: Bone 2009; 46(4): 1038-42
Abstract: Longevity has resulted in a greater proportion of the population entering a time of life when increasing bone fragility and falls predispose to fractures, particularly nonvertebral fractures. Women over 80 years of age constitute 10% of the population but contribute 30% of all fractures and 60% of all nonvertebral fractures. Despite this, few studies have examined antifracture efficacy of treatments in this high-risk group and none has provided evidence for benefits beyond 3 years.To determine whether strontium ranelate reduces the risk of vertebral and nonvertebral fractures during 5 years, we analyzed a subgroup of 1489 female patients over 80 years of age (mean 83.5+/-3.0 years) with osteoporosis from the SOTI (spinal osteoporosis therapeutic intervention) and TROPOS (treatment of peripheral osteoporosis) studies randomized to strontium ranelate 2 g/d or placebo. All received a supplement of calcium plus vitamin D.By intention to treat, vertebral fracture risk was reduced by 31% (relative risk, RR=0.69; 95% confidence interval, CI 0.52-0.92), nonvertebral fracture risk by 27% (RR=0.73; 95% CI 0.57-0.95), major nonvertebral fracture risk by 33% (RR=0.67; 95% CI 0.50-0.89) and hip fracture risk by 24% (RR=0.76; 95% CI 0.50-1.15, not significant). Treatment was cost-saving as it decreased cost and increased QALYs and life-years.Strontium ranelate safely produced a significant reduction in vertebral and nonvertebral fracture risk during 5 years in postmenopausal women over 80 years of age and was cost saving.
Gov't Doc #: 20026265
URI: http://ahro.austin.org.au/austinjspui/handle/1/10940
DOI: 10.1016/j.bone.2009.12.006
URL: https://pubmed.ncbi.nlm.nih.gov/20026265
Type: Journal Article
Subjects: Aged, 80 and over
Bone Density.drug effects
Bone Density Conservation Agents.therapeutic use
Bone and Bones.drug effects
Calcium, Dietary.therapeutic use
Female
Hip Fractures.prevention & control
Humans
Intention to Treat Analysis
Organometallic Compounds.therapeutic use
Osteoporosis, Postmenopausal.drug therapy
Quality of Life
Spinal Fractures.prevention & control
Thiophenes.therapeutic use
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.